These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 25646307)

  • 1. IFN-β treatment requires B cells for efficacy in neuroautoimmunity.
    Schubert RD; Hu Y; Kumar G; Szeto S; Abraham P; Winderl J; Guthridge JM; Pardo G; Dunn J; Steinman L; Axtell RC
    J Immunol; 2015 Mar; 194(5):2110-6. PubMed ID: 25646307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
    Axtell RC; de Jong BA; Boniface K; van der Voort LF; Bhat R; De Sarno P; Naves R; Han M; Zhong F; Castellanos JG; Mair R; Christakos A; Kolkowitz I; Katz L; Killestein J; Polman CH; de Waal Malefyt R; Steinman L; Raman C
    Nat Med; 2010 Apr; 16(4):406-12. PubMed ID: 20348925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
    Kleist C; Mohr E; Gaikwad S; Dittmar L; Kuerten S; Platten M; Mier W; Schmitt M; Opelz G; Terness P
    J Transl Med; 2016 May; 14(1):99. PubMed ID: 27131971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-β regulates Th17 differentiation partly through the inhibition of osteopontin in experimental autoimmune encephalomyelitis.
    Zhao Q; Cheng W; Xi Y; Cao Z; Xu Y; Wu T; Li C; Niu X; Chen G
    Mol Immunol; 2018 Jan; 93():20-30. PubMed ID: 29127843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic role of interferon-γ in experimental autoimmune encephalomyelitis is mediated through a tolerogenic subset of splenic CD11b
    Arellano G; Acuña E; Loda E; Moore L; Tichauer JE; Castillo C; Vergara F; Burgos PI; Penaloza-MacMaster P; Miller SD; Naves R
    J Neuroinflammation; 2024 May; 21(1):144. PubMed ID: 38822334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
    Kala M; Rhodes SN; Piao WH; Shi FD; Campagnolo DI; Vollmer TL
    Exp Neurol; 2010 Jan; 221(1):136-45. PubMed ID: 19879259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells.
    Sweeney CM; Lonergan R; Basdeo SA; Kinsella K; Dungan LS; Higgins SC; Kelly PJ; Costelloe L; Tubridy N; Mills KH; Fletcher JM
    Brain Behav Immun; 2011 Aug; 25(6):1170-81. PubMed ID: 21420486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
    Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS
    CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.
    Ramgolam VS; Sha Y; Marcus KL; Choudhary N; Troiani L; Chopra M; Markovic-Plese S
    J Immunol; 2011 Apr; 186(7):4518-26. PubMed ID: 21368231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate.
    Begum-Haque S; Christy M; Ochoa-Reparaz J; Nowak EC; Mielcarz D; Haque A; Kasper LH
    J Neuroimmunol; 2011 Mar; 232(1-2):136-44. PubMed ID: 21111489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
    Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
    J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
    Nischwitz S; Faber H; Sämann PG; Domingues HS; Krishnamoorthy G; Knop M; Müller-Sarnowski F; Yassouridis A; Weber F
    Acta Neurol Scand; 2014 Jul; 130(1):46-52. PubMed ID: 24571587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.
    Aharoni R; Eilam R; Stock A; Vainshtein A; Shezen E; Gal H; Friedman N; Arnon R
    J Neuroimmunol; 2010 Aug; 225(1-2):100-11. PubMed ID: 20554028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-α.
    Vasquez M; Consuegra-Fernández M; Aranda F; Jimenez A; Tenesaca S; Fernandez-Sendin M; Gomar C; Ardaiz N; Di Trani CA; Casares N; Lasarte JJ; Lozano F; Berraondo P
    J Immunol; 2019 Aug; 203(3):696-704. PubMed ID: 31209101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of experimental autoimmune encephalomyelitis in the C57BL/6J mouse by NK1.1+, DX5+, alpha beta+ T cells.
    Fritz RB; Zhao ML
    J Immunol; 2001 Mar; 166(6):4209-15. PubMed ID: 11238673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-β regulates dendritic cell activation and migration in experimental autoimmune encephalomyelitis.
    Pennell LM; Fish EN
    Immunology; 2017 Nov; 152(3):439-450. PubMed ID: 28646573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate.
    D Alessandro J; Garofalo K; Zhao G; Honan C; Duffner J; Capila I; Fier I; Kaundinya G; Kantor D; Ganguly T
    CNS Neurol Disord Drug Targets; 2017; 16(6):714-723. PubMed ID: 28240190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.